Comparative Pharmacology
Head-to-head clinical analysis: SODIUM CHROMATE CR 51 versus XENOVIEW.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM CHROMATE CR 51 versus XENOVIEW.
SODIUM CHROMATE CR 51 vs XENOVIEW
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiolabeled sodium chromate (51Cr) binds to red blood cells, tagging them for survival studies. 51Cr emits gamma radiation, allowing detection and quantification of RBC mass and survival via scintillation counting or imaging.
Xenoview is a paramagnetic contrast agent for MRI that enhances T1 relaxation by shortening the longitudinal relaxation time of water protons in tissues where it accumulates, thereby increasing signal intensity on T1-weighted images.
Intravenous injection, 5-30 microcuries (0.185-1.11 MBq) as a single dose.
Not applicable (diagnostic agent, not therapeutic); refer to imaging protocol.
None Documented
None Documented
The biological half-life is approximately 27–30 days. Clinically, gradual clearance from blood and tissues occurs over weeks to months.
Terminal elimination half-life is 3-5 hours in patients with normal renal function; may be prolonged in renal impairment.
Primarily renal. Approximately 90% of absorbed dose is excreted in urine within 48 hours. Fecal excretion accounts for less than 5%.
Primarily renal excretion (60-70% unchanged drug), with 20-25% biliary/fecal elimination.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical